The Latest Breaking News from Obesity

A diabetes drug is all the rage among Hollywood’s elite, but folks who need the drug are struggling to get it

Amgen stock jumped Tuesday on a promising update for its potential rival to obesity treatments from Novo Nordisk and Eli Lilly.

Food labels displaying the amount of exercise needed to burn off the calories in the product are being touted as a way to reduce obesity, but not everyone is convinced.

A drug called semaglutide, which is approved for adults with obesity or overweight, also helps adolescents shed pounds and have healthier hearts, according to a new study. Read more on Dynamite News:

Obesity and diabetes rates are soaring, so why hasn’t a law banning sugary beverages for children been enforced?

Rising life expectancy is one of the great success stories. If you were born in 1870, you’d expect to live until you were 30. But if you were born today, you’d expect to live to 72, and the UN predicts it will continue to rise to 82 years by 2100.…

NHS figures reveal rates of obesity significantly higher in deprived areas of the capital

Boys are more likely to be obese than girls, a report says.

Novo Nordisk A/S’s weekly shot that reduces obesity in adults returned promising results in teens, according to a study that adds to a growing wave of potential interventions for the stubborn condition.

"We’ve now got a whole team at Manchester [hospitals trust] that are really skilled in amputating limbs because people have had diabetes and circulatory problems."

DestinationXL Group (DXLG) is the leading retailer of men's big & tall clothing. This market continues to grow due to rising rates of obesity all over the world. This means that DXLG has further upside and investors should consider accumulating the stock during the bear market.